Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) FCF Margin: 2009-2025

Historic FCF Margin for Amicus Therapeutics (FOLD) over the last 14 years, with Sep 2025 value amounting to 20.87%.

  • Amicus Therapeutics' FCF Margin rose 3735.00% to 20.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.62%, marking a year-over-year increase of 800.00%. This contributed to the annual value of -7.09% for FY2024, which is 1208.00% up from last year.
  • Per Amicus Therapeutics' latest filing, its FCF Margin stood at 20.87% for Q3 2025, which was up 211.58% from -18.70% recorded in Q2 2025.
  • Amicus Therapeutics' 5-year FCF Margin high stood at 20.87% for Q3 2025, and its period low was -110.27% during Q1 2021.
  • Its 3-year average for FCF Margin is -9.30%, with a median of -16.48% in 2024.
  • In the last 5 years, Amicus Therapeutics' FCF Margin soared by 9,623bps in 2023 and then plummeted by 3,575bps in 2025.
  • Quarterly analysis of 5 years shows Amicus Therapeutics' FCF Margin stood at -87.97% in 2021, then tumbled by 675bps to -94.73% in 2022, then skyrocketed by 9,623bps to 1.50% in 2023, then tumbled by 431bps to -2.81% in 2024, then skyrocketed by 3,735bps to 20.87% in 2025.
  • Its FCF Margin stands at 20.87% for Q3 2025, versus -18.70% for Q2 2025 and 6.02% for Q1 2025.